Literature DB >> 12438640

A novel protease processing site in the transframe protein of human T-cell leukemia virus type 1 PR76(gag-pro) defines the N terminus of RT.

Gisela Heidecker1, Shawn Hill, Patricia A Lloyd, David Derse.   

Abstract

The genomic RNA of human T-cell leukemia virus type 1 encodes three polyproteins, Gag, Gag-Pro, and Gag-Pro-Pol, which are translated as a result of no, one, and two frameshifts, respectively. In this report we demonstrate that the 77 residues encoded at the C terminus of the Gag-Pro precursor can be collectively detected as an 8-kDa transframe protein (TFP) in virions. Mutant viruses with a C-terminally truncated TFP (19, 32, or 50 residues) had essentially a wild-type phenotype in vitro. However, a virus mutant that encoded only the Gag and Gag-Pro-Pol polyproteins due to a mutation in the second frameshift site, and hence did not produce TFP, was noninfectious. Mutation analysis of the proteolytic cleavage site between PR and TFP revealed the presence of an additional site and the existence of a p1 peptide separating protease and TFP. While removal of the cleavage site at the PR-p1 junction had a modest effect on virus replication, mutation of the p1-TFP cleavage site led to noninfectious virus and the loss of reverse transcriptase activity. Determination of the amino-terminal sequence of a hemagglutinin-tagged RT demonstrated that the same site is used in processing the Gag-Pro-Pol precursor and thus defines the start of mature RT. Neither mutation alone or in combination caused changes in the amounts or processing patterns of the Gag polyprotein, indicating that protease is active independent of its C terminus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438640      PMCID: PMC136720          DOI: 10.1128/jvi.76.24.13101-13105.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase.

Authors:  J M Louis; S Oroszlan; J Tözsér
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

2.  Substrates and inhibitors of human T-cell leukemia virus type I protease.

Authors:  Y S Ding; D H Rich; R A Ikeda
Journal:  Biochemistry       Date:  1998-12-15       Impact factor: 3.162

3.  X-I and X-II open reading frames of HTLV-I are not required for virus replication or for immortalization of primary T-cells in vitro.

Authors:  D Derse; J Mikovits; F Ruscetti
Journal:  Virology       Date:  1997-10-13       Impact factor: 3.616

4.  Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo.

Authors:  J T Bartoe; B Albrecht; N D Collins; M D Robek; L Ratner; P L Green; M D Lairmore
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Proteolytic processing of the human T-cell lymphotropic virus 1 reverse transcriptase: identification of the N-terminal cleavage site by mass spectrometry.

Authors:  P G Agbuya; N E Sherman; L K Moen
Journal:  Arch Biochem Biophys       Date:  2001-08-01       Impact factor: 4.013

6.  Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors.

Authors:  D Derse; S A Hill; P A Lloyd; B A Morse
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.

Authors:  J Tözsér; G Zahuczky; P Bagossi; J M Louis; T D Copeland; S Oroszlan; R W Harrison; I T Weber
Journal:  Eur J Biochem       Date:  2000-10

8.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.

Authors:  M Yoshida; I Miyoshi; Y Hinuma
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

9.  Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo.

Authors:  N D Collins; G C Newbound; B Albrecht; J L Beard; L Ratner; M D Lairmore
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  6 in total

Review 1.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

2.  Development of a cytotoxic T-cell assay in rabbits to evaluate early immune response to human T-lymphotropic virus type 1 infection.

Authors:  Rashade A H Haynes; Andrew J Phipps; Brenda Yamamoto; Patrick Green; Michael D Lairmore
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

3.  Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples.

Authors:  Michael S Mitchell; Ellen T Bodine; Shawn Hill; Gerald Princler; Patricia Lloyd; Hiroaki Mitsuya; Masao Matsuoka; David Derse
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

4.  Human T-cell leukemia virus type 1 blunts signaling by interferon alpha.

Authors:  Xuan Feng; Lee Ratner
Journal:  Virology       Date:  2008-01-29       Impact factor: 3.616

5.  Late assembly motifs of human T-cell leukemia virus type 1 and their relative roles in particle release.

Authors:  Gisela Heidecker; Patricia A Lloyd; Kristi Fox; Kunio Nagashima; David Derse
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

6.  The role of WWP1-Gag interaction and Gag ubiquitination in assembly and release of human T-cell leukemia virus type 1.

Authors:  Gisela Heidecker; Patricia A Lloyd; Ferri Soheilian; Kunio Nagashima; David Derse
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.